Neuroinflammation is a pervasive feature of
Alzheimer's disease (AD) and characterized by activated microglia, increased proinflammatory
cytokines and/or infiltrating immune cells. T helper 17 (Th17) cells are found in AD brain parenchyma and
interleukin-17A (IL-17A) is identified around deposits of aggregated
amyloid β
protein (Aβ). However, the role of
IL-17A in AD pathogenesis remains elusive. We overexpressed
IL-17A in an AD mouse model via recombinant adeno-associated virus serotype 5 (rAAV5)-mediated intracranial gene delivery. AD model mice subjected to injection of a vehicle (PBS) or rAAV5 carrying the lacZ gene served as controls.
IL-17A did not exacerbate
neuroinflammation in IL-17A-overexpressing mice. We found that
IL-17A overexpression markedly improved
glucose metabolism, decreased soluble Aβ levels in the hippocampus and cerebrospinal fluid, drastically reduced
cerebral amyloid angiopathy, and modestly but significantly improved anxiety and learning deficits. Moreover, the
ATP-binding cassette subfamily A member 1 (ABCA1), which can transport Aβ from the brain into the blood circulation, significantly increased in IL-17A-overexpressing mice. In vitro treatment of brain endothelial bEnd.3 cells with
IL-17A induced a dose-dependent increase in
protein expression of ABCA1 through ERK activation. Our study suggests that
IL-17A may decrease Aβ levels in the brain by upregulating ABCA1 in blood-brain barrier endothelial cells.